For the second primary endpoint at Week 72, 36.8% of people treated with semaglutide 2.4 mg achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% on placebo (EDP, 14.4%
106 LiW.MaL.YangG.GanW.-B
The multi-task loss function employed weighted binary cross-entropy with equal weighting ( = 0.5) across active receptors: A three-stage transfer learning approach was implemented to address the limited availability of GIPR training data relative to GCGR and GLP1R
Rather than obsessing over losing weight quickly, Lizzo seems to be losing weight very slowly, in a methodical way that aligns with her mental and emotional health
In recent years, GLP-1 medications like Ozempic have progressed from a specialised diabetes treatment into a more widespread weight loss tool used by a wide range of people globally
37 CONCLUSION In consideration of clinical trials published thus far, oral semaglutide has demonstrated efficacy in terms of A1C and weight reduction when used as an addon to a variety of background glucose-lowering regimens in patients with T2DM and inadequate glycemic control
